<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-91332" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Uremic Encephalopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Olano</surname>
            <given-names>Claudia G.</given-names>
          </name>
          <aff>Harbor UCLA Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akram</surname>
            <given-names>Sami M.</given-names>
          </name>
          <aff>University of Florida, Gainesville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatt</surname>
            <given-names>Harshil</given-names>
          </name>
          <aff>Goshen Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Claudia Olano declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sami Akram declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Harshil Bhatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-91332.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Uremic encephalopathy is a cerebral dysfunction caused by the accumulation of toxins due to acute or chronic renal failure.&#x000a0;This condition typically&#x000a0;develops in patients with acute or chronic renal failure whose estimated glomerular filtration rate is below 15 mL/min. The clinical presentation varies widely, from subtle to florid, and the clinical course invariably progresses if left untreated. The syndrome likely results from alterations in hormonal metabolism, retention of uremic solutes, changes in electrolyte and acid-base homeostasis, blood-brain barrier transport, vascular reactivity issues, and inflammation.&#x000a0;Urea is the most commonly measured indicator of uremic toxins, but many other substances are being studied as contributors to uremia.</p>
        <p>Diagnosis of uremic encephalopathy is challenging because there are no specific clinical, laboratory, or imaging findings. The condition is often diagnosed retrospectively when symptoms improve after dialysis or kidney transplantation. If symptoms do not improve after clearing toxic solutes, other potential causes should be investigated.&#x000a0;Early recognition and treatment are crucial, as&#x000a0;uremic encephalopathy is an absolute indication for initiating renal replacement therapy. Management also includes addressing chronic kidney disease with treatments such as erythropoiesis-stimulating agents, phosphate binders, calcium supplements, and nutritional modifications. This activity emphasizes&#x000a0;the evaluation and treatment of uremic encephalopathy, emphasizing the role of the interprofessional team in patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical signs and symptoms of uremic encephalopathy in patients with acute or chronic renal failure.</p></list-item><list-item><p>Assess and monitor the effectiveness of dialysis or kidney transplantation in resolving symptoms of uremic encephalopathy.</p></list-item><list-item><p>Select appropriate diagnostic tools, such as EEG or neuroimaging, to aid in diagnosing and managing uremic encephalopathy.</p></list-item><list-item><p>Coordinate with the interprofessional healthcare team to develop comprehensive treatment plans and ensure optimal outcomes for patients with uremic encephalopathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91332&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91332">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-91332.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Uremic encephalopathy is defined as cerebral dysfunction caused by the accumulation of toxins due to&#x000a0;acute or chronic renal failure.<xref ref-type="bibr" rid="article-91332.r1">[1]</xref><xref ref-type="bibr" rid="article-91332.r2">[2]</xref><xref ref-type="bibr" rid="article-91332.r3">[3]</xref>&#x000a0;This condition typically&#x000a0;develops in patients with acute or chronic renal failure whose estimated glomerular filtration rate (eGFR) is below 15 mL/min.<xref ref-type="bibr" rid="article-91332.r3">[3]</xref> The clinical presentation of&#x000a0;uremic encephalopathy is broad, varying from subtle to florid, and the clinical course is always progressive when left untreated. Uremic encephalopathy is at least partially reversible with the initiation of renal replacement therapy, making it a clear indication to start such treatment.<xref ref-type="bibr" rid="article-91332.r2">[2]</xref></p>
        <p>The syndrome likely results from alterations in hormonal metabolism, retention of uremic solutes, changes in electrolyte and acid-base homeostasis, blood-brain barrier transport, changes in vascular reactivity, and inflammation. Diagnosis of uremic encephalopathy is challenging, as there are no specific clinical, laboratory, or imaging findings. The condition is often diagnosed retrospectively when symptoms improve after dialysis or kidney transplantation.&#x000a0;If symptoms do not improve after clearing toxic solutes, other potential causes should be investigated.<xref ref-type="bibr" rid="article-91332.r4">[4]</xref></p>
      </sec>
      <sec id="article-91332.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Causes of uremic encephalopathy generally include factors that lead to the accumulation of uremic toxins, such as acute kidney injury and chronic kidney disease (CKD). Many compounds, known as uremic toxins, have been implicated in the pathogenesis of uremic encephalopathy.</p>
        <p>Urea is the most studied toxin and is used as a surrogate for other uremic toxins. While severe cognitive changes from uremic encephalopathy develop when eGFR falls below 15 mL/min, mild-to-moderate cognitive changes can be identified at eGFR levels between 40 and 60 mL/min.<xref ref-type="bibr" rid="article-91332.r3">[3]</xref><xref ref-type="bibr" rid="article-91332.r5">[5]</xref></p>
        <p>Generally, uremic toxins build up in a patient's blood when they develop acute kidney injury due to various reasons. They either cannot clear solutes through renal replacement therapy or fail to respond to therapy. The causes of this buildup are extensive and include drugs, toxins, prolonged hypotension, dehydration, sepsis, and blood loss.<xref ref-type="bibr" rid="article-91332.r6">[6]</xref><xref ref-type="bibr" rid="article-91332.r7">[7]</xref> Uremic encephalopathy can also develop in&#x000a0;patients with CKD when their eGFR falls due to acute insults such as infection, drugs, excessive vomiting, or diarrhea. Additionally, patients on hemodialysis can develop uremic encephalopathy if they receive inadequate dialysis due to factors like noncompliance or arteriovenous fistula dysfunction.<xref ref-type="bibr" rid="article-91332.r8">[8]</xref></p>
      </sec>
      <sec id="article-91332.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The absence of specific defining characteristics of uremia complicates data interpretation. However, severe encephalopathy appears to be rare in patients with progressive CKD, as most of them&#x000a0;undergo renal replacement therapy before severe encephalopathy ensues. Uremic encephalopathy can also occur with acute kidney injury, where&#x000a0;the decline in GFR is less predictable and more rapid.<xref ref-type="bibr" rid="article-91332.r4">[4]</xref></p>
        <p>Cognitive dysfunction&#x000a0;is multifactorial, potentially stemming from vascular injury, endothelial inflammation, or direct effects of neurotoxins, and&#x000a0;can affect up to 60% of patients with CKD. The cause and effect of the relationships between neurotoxins and cognitive dysfunction are uncertain. Therefore, it is challenging to estimate the prevalence of uremic encephalopathy. In a pediatric study, uremic encephalopathy was observed in 40% of patients with a blood urea nitrogen (BUN) level exceeding 90 mg/dL. As BUN levels increased, the propensity of these children to develop convulsions increased.<xref ref-type="bibr" rid="article-91332.r9">[9]</xref></p>
        <p>Uremic encephalopathy significantly increases the morbidity and mortality in CKD patients.<xref ref-type="bibr" rid="article-91332.r1">[1]</xref>&#x000a0;Symptoms can be reversed by initiating dialysis and clearing toxic solutes in acute kidney injury. In patients with end-stage renal disease (ESRD), the condition is also reversible through dialysis or kidney transplantation. Severe complications, such as seizures or coma, can be fatal.&#x000a0;Early recognition of&#x000a0;neurological signs in patients with impaired renal function is crucial to prevent morbidity and mortality. Prompt initiation of dialytic therapy can reduce mortality rates.<xref ref-type="bibr" rid="article-91332.r10">[10]</xref></p>
        <p>Notably, racial predilection does not exist, and there is no link between gender and the incidence of uremic encephalopathy. Uremic encephalopathy may occur at any age.</p>
      </sec>
      <sec id="article-91332.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>A proposed mechanism of uremic encephalopathy is the accumulation of neurotoxins.<xref ref-type="bibr" rid="article-91332.r3">[3]</xref><xref ref-type="bibr" rid="article-91332.r5">[5]</xref>&#x000a0;Over 130 chemicals have been identified as potential neurotoxins.<xref ref-type="bibr" rid="article-91332.r11">[11]</xref>&#x000a0;These include&#x000a0;urea, indoxyl sulfate, guanidine compounds, indolic acid, phenols, and carnitine. Lanthionine, a derivative of sulfur-containing amino acids, is more recently recognized as a uremic toxin.<xref ref-type="bibr" rid="article-91332.r12">[12]</xref>&#x000a0;The roles of these individual compounds in producing the clinical picture of uremic encephalopathy are unclear. More basic science research is needed to understand the functions of these chemicals in causing uremic encephalopathy. The European Uremic Toxins (EUTox) workgroup, an international consortium of academic and medical researchers, strives to understand these compounds' roles. These chemicals belong to diverse and unrelated groups, such as peptides, ions, and products of lipid and carbohydrate metabolism. An ideal classification of uremic toxins does not exist, but based on their physicochemical properties, they may be classified as water-soluble, protein-bound, and middle molecules. Although no common pathway has been identified, 3 processes may contribute overall&#x02014;an imbalance in inhibitory and excitatory neurotransmitters, neuronal degeneration, and vascular inflammation.<xref ref-type="bibr" rid="article-91332.r13">[13]</xref></p>
        <p>According to a hypothesis, plasma and cerebrospinal fluid levels of glycine increase, whereas glutamine and gamma-aminobutyric acid (GABA) decrease. The accumulation of guanidino compounds, resulting from L-arginine metabolism, leads to the activation of excitatory <italic toggle="yes">N</italic>-methyl-D-aspartate (NMDA) receptors and further inhibits inhibitory GABA receptors.<xref ref-type="bibr" rid="article-91332.r2">[2]</xref><xref ref-type="bibr" rid="article-91332.r14">[14]</xref><xref ref-type="bibr" rid="article-91332.r15">[15]</xref> Another proposed mechanism is hyperparathyroidism, which increases the calcium content in brain cells.<xref ref-type="bibr" rid="article-91332.r16">[16]</xref> However, encephalopathy improves with dialysis, which does not immediately affect parathyroid hormone levels. Recently, a link between vascular endothelial dysfunction and cognitive dysfunction has been recognized, potentially contributing to the clinical syndrome of uremic encephalopathy.</p>
        <p>The blood pressure regulatory neurons are located in the rostral ventrolateral medulla (RVLM), which contains the presympathetic neurons. When exposed to high concentrations of uric acid, indoxyl sulfate, and methyl guanidine, RVLM neuronal activity increases. The subsequent use of antioxidant drugs results in the cessation of RVLM activity, which suggests that reactive oxidant species have a central role in the development of the clinical syndrome of uremic encephalopathy. While urea is used as a surrogate marker for neurotoxins and is lowered with dialysis, there is no credible evidence linking urea directly to encephalopathy. Recent studies have shown that indoxyl sulfate can cause vascular inflammation and neurological symptoms.<xref ref-type="bibr" rid="article-91332.r17">[17]</xref>&#x000a0;The common mechanism appears to be oxidative stress.</p>
        <p>Oxidative stress can alter mitochondrial function, leading to dysfunctional mitochondria that produce more uremic toxins, creating a self-perpetuating cycle.<xref ref-type="bibr" rid="article-91332.r11">[11]</xref>&#x000a0;The metabolism of purines and the urea cycle requires enzymes located within the mitochondria. Therefore, in patients with uremic encephalopathy, there is an acquired mitochondrial defect. As a result, uremic brains are less capable of utilizing ATP-requiring pathways compared to healthy brains. Reactive oxygen species accumulate due to mitochondrial dysfunction, further aggravating oxidative stress. This oxidative stress results in endothelial dysfunction, myelin injury, and nitration of brain proteins, leading to the production of more uremic toxins.<xref ref-type="bibr" rid="article-91332.r18">[18]</xref></p>
      </sec>
      <sec id="article-91332.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Uremic encephalopathy is a clinical syndrome with no established diagnostic criteria. The clinical presentation is variable and depends on the rate of progression of the underlying kidney disease. In patients with a slow decline in eGFR, the primary signs include fatigue, anorexia, weight loss, and nausea. Cognitive dysfunction in these patients is slow, progressive, and subtle.<xref ref-type="bibr" rid="article-91332.r19">[19]</xref> Symptoms Symptoms may include restlessness, drowsiness, diminished ability to concentrate, and slowed cognitive functions. Psychometric testing is required to identify the involvement of the central nervous system.</p>
        <p>At the other end of the spectrum are patients with a rapid decline in eGFR. These patients can present with more severe features of uremic encephalopathy, such as confusion, delirium, seizures, disorientation, emotional volatility, and coma.<xref ref-type="bibr" rid="article-91332.r20">[20]</xref>&#x000a0;A physical examination reveals cognitive dysfunction, including abnormalities in memory, judgment, and the ability to perform calculations. Hyperreflexia, asterixis, papilledema, and nystagmus are frequently present. Additionally, neuropathy and myopathy may also be observed.</p>
      </sec>
      <sec id="article-91332.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Uremic encephalopathy is an absolute indication to start renal replacement therapy, making early diagnosis essential. This clinical syndrome has a variable and subtle presentation, and there is no confirmatory test, leading to delays in diagnosis. During the evaluation, excluding conditions that may mimic uremic encephalopathy, such as infection, osmotic demyelination, subdural hematomas, hypertensive encephalopathy, cerebrovascular accidents, and disequilibrium syndrome, is crucial.</p>
        <p>
<bold>Laboratory Evaluation</bold>
</p>
        <p>Specific confirmatory tests to diagnose uremic encephalopathy do not exist. Renal function tests reveal markedly elevated BUN and creatinine levels in uremic encephalopathy.<xref ref-type="bibr" rid="article-91332.r21">[21]</xref> The workup should be rapid and geared toward excluding other conditions that mimic uremic&#x000a0;encephalopathy, which is ubiquitous in patients with advanced CKD. A complete&#x000a0;blood count (CBC) should be done to evaluate leucocytosis, which could indicate an underlying infection. Serum electrolyte and glucose measurements should be considered to rule out hypernatremia, hyponatremia, hyperglycemia, and hyperosmolar states as causes of encephalopathy. Calcium, magnesium, phosphorus, and parathyroid hormone levels should be assessed as they can worsen metabolic encephalopathy. Lactic acid levels and a toxicology screen should also be ordered. A lumbar puncture does not help diagnose uremic encephalopathy but may be required if no improvement is seen after renal replacement therapy to evaluate for other neurological conditions. C-reactive protein can be measured to investigate the possibility of infection if there is clinical suspicion of infection.</p>
        <p>
<bold>Neurological Evaluation&#x000a0;&#x000a0;</bold>
</p>
        <p>The electroencephalogram (EEG) is nondiagnostic but is often performed an EEG is in patients to exclude underlying seizures. EEG findings in uremic encephalopathy include a loss of alpha&#x000a0;frequency waves, overall slowing, and intermittent bursts of theta and delta waves with slow background activity. These findings are nonspecific. The degree of EEG wave slowing is directly proportional to the worsening renal function. After the initiation of dialysis, the EEG changes stabilize but may not return to baseline. Some improvement may occur over several months.<xref ref-type="bibr" rid="article-91332.r22">[22]</xref></p>
        <p>
<bold>Cognitive Tests</bold>
</p>
        <p>Cognitive tests that can be used include the trail-making test (which measures psychomotor speed), the short-term memory test, and the choice reaction time test (which measures simple decision-making).</p>
        <p>
<bold>Neuroimaging</bold>
</p>
        <p>A computed tomography (CT) scan of the brain can exclude focal lesions. Magnetic resonance imaging (MRI) studies in uremic patients show widespread brain involvement.<xref ref-type="bibr" rid="article-91332.r23">[23]</xref>&#x000a0;Abnormalities can be found in the cortex, subcortical white matter, basal ganglia, and hippocampus.<xref ref-type="bibr" rid="article-91332.r24">[24]</xref>&#x000a0;These extensive lesions result in a variable clinical presentation. Based on MRI findings, patients with uremic encephalopathy may be grouped into 3 types:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cortical and subcortical involvement, with posterior reversible leukoencephalopathy syndrome (PRES) potentially present concurrently.<xref ref-type="bibr" rid="article-91332.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Bilateral basal ganglia involvement, which is commonly observed in diabetic patients.<xref ref-type="bibr" rid="article-91332.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>White matter involvement only, which is rare.</p>
          </list-item>
        </list>
        <p>The presence of PRES&#x000a0;in imaging&#x000a0;studies performed for uremic encephalopathy suggests a close relationship between vascular and neuronal dysfunction, as described in the pathogenesis of uremic&#x000a0;encephalopathy. A published case demonstrated that MRI changes, such as increased signal intensity, are reversible after several sessions of intermittent hemodialysis compared to continuous ambulatory peritoneal dialysis (CAPD). MRI changes involve multiple brain areas; currently, there is no evidence to delineate the reversible and nonreversible changes in functional imaging. In general, intermittent hemodialysis can clear uremic toxins faster than CAPD.</p>
      </sec>
      <sec id="article-91332.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Uremic encephalopathy is an absolute indication to initiate renal replacement therapy. A study observed 3 cases of uremic encephalopathy in anuric patients undergoing peritoneal dialysis despite adequate <italic toggle="yes">Kt/V</italic> (where <italic toggle="yes">K</italic> is dialyzer clearance of urea [L/min], <italic toggle="yes">t</italic> is dialysis time [minutes], and <italic toggle="yes">V</italic> is the distribution volume of body fluids or urea [liters]).&#x000a0;All&#x000a0;cases were resolved with the initiation of hemodialysis. These patients also had low albumin levels and evidence of malnutrition, which could be contributing factors.<xref ref-type="bibr" rid="article-91332.r13">[13]</xref>&#x000a0;Often, a therapeutic trial with renal replacement therapy is warranted in the setting of uremia to evaluate for symptom improvement. Management of CKD should be implemented simultaneously,&#x000a0;including the use of&#x000a0;erythropoiesis-stimulating agents, phosphate binders, calcium replacement, and nutrition modifications.</p>
        <p>Providers should address the following factors when managing uremic encephalopathy, which are included in the standard management of any patient with ESRD:</p>
        <list list-type="bullet">
          <list-item>
            <p>Adequacy of dialysis</p>
          </list-item>
          <list-item>
            <p>Correction of anemia</p>
          </list-item>
          <list-item>
            <p>Regulation of calcium and phosphate metabolism</p>
          </list-item>
        </list>
        <p>Clinical evidence indicates that intermittent hemodialysis is more effective than CAPD for solute clearance. However, this method carries the risk of causing or precipitating dialysis disequilibrium syndrome due to rapid osmotic changes at the start of intermittent hemodialysis.<xref ref-type="bibr" rid="article-91332.r26">[26]</xref>&#x000a0;Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/98826">Dialysis Dysequilibrium Syndrome</ext-link>," for further information. Mannitol can be used to prevent this condition in the first few intermittent hemodialysis sessions. Mannitol (25 g) can be administered for the first 3 sessions before starting hemodialysis.</p>
        <p>Studies have shown that the measured blood osmolality change is reduced by 60% with mannitol (a 10 mmol/kg fall in plasma osmolality was decreased to 4.3 mmol/kg with intravenous mannitol before intermittent hemodialysis). The symptoms of dialysis disequilibrium syndrome were mild in the mannitol group and occurred in 10% of patients compared to 67% in the non-mannitol group despite similar ultrafiltration rates.<xref ref-type="bibr" rid="article-91332.r27">[27]</xref></p>
        <p>The key to avoiding uremic encephalopathy is initiating renal replacement therapy in a timely manner. Most guidelines suggest making preparations for renal replacement therapy access or referral for renal transplant when the eGFR falls below 20 mL/min. Previously, the Fistula First initiative encouraged fistulas for all patients. However, the 2019 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines now endorse the concept of "right access, in the right patient, at the right time, for the right reasons" to provide more patient-centered care.<xref ref-type="bibr" rid="article-91332.r28">[28]</xref></p>
      </sec>
      <sec id="article-91332.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Uremic encephalopathy is a diagnosis of exclusion. The following should be considered in the differential diagnosis:&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Wernicke-Korsakoff encephalopathy</p>
          </list-item>
          <list-item>
            <p>Hypertensive encephalopathy</p>
          </list-item>
          <list-item>
            <p>Hyperosmolar coma</p>
          </list-item>
          <list-item>
            <p>Disequilibrium syndrome</p>
          </list-item>
          <list-item>
            <p>Metabolic encephalopathy&#x000a0;<xref ref-type="bibr" rid="article-91332.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Sepsis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Fluid and electrolyte disturbances, such as hyponatremia and hypermagnesemia</p>
          </list-item>
          <list-item>
            <p>Drug toxicity&#x000a0;</p>
          </list-item>
          <list-item>
            <p>PRES&#x000a0;<xref ref-type="bibr" rid="article-91332.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Osmotic demyelination syndrome</p>
          </list-item>
          <list-item>
            <p>Hepatic encephalopathy</p>
          </list-item>
          <list-item>
            <p>Hypoglycemia&#x000a0;</p>
          </list-item>
        </list>
        <p>A mnemonic&#x000a0;to remember a set of conditions that lead to diffuse cortical injury on MRI is &#x0201c;CRUMPLED.&#x0201d; In this mnemonic, C stands for Creutzfeldt-Jakob disease, R stands for reversible cerebral vasoconstriction syndrome, U is for uremic encephalopathy, M is for mitochondrial cytopathy/encephalopathy, P stands for prolonged seizure or PRES, L stands for liver disease, E is for encephalitis/infectious, and D is for diabetes mellitus causing hypoglycemia.</p>
      </sec>
      <sec id="article-91332.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>With the initiation of renal replacement therapy, the clinical syndrome of uremic encephalopathy usually improves, although recovery may take days to weeks. EEG changes may require several months to recover and may not return to baseline. Some cognitive changes in the brain may be irreversible, underscoring the importance of initiating renal replacement therapy before the onset of uremic encephalopathy. Uremic encephalopathy is typically more severe in patients with acute kidney injury due to the neurotoxic effects of nitrogenous solutes and other osmotically active toxins.<xref ref-type="bibr" rid="article-91332.r30">[30]</xref></p>
      </sec>
      <sec id="article-91332.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Some complications of uremic encephalopathy include seizures, coma, and death. Initiation of renal replacement therapy can partially reverse uremic encephalopathy; however, some cognitive changes may become permanent.</p>
      </sec>
      <sec id="article-91332.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>A neurologist should be consulted if symptoms of uremic encephalopathy do not improve after the initiation of dialysis therapy. For patients with ESRD, it is important to consult a vascular surgeon for vascular access placement. If a fistula is inappropriate, a catheter may need to be placed. Dietary modifications should be managed by referring patients with ESRD to a dietitian familiar with renal disorders.</p>
      </sec>
      <sec id="article-91332.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Nephrologists should closely monitor patients with advanced-stage CKD in the outpatient setting. Regular monitoring of eGFR is essential to initiate dialysis before uremic encephalopathy develops. To prevent malnutrition in ESRD, patients should maintain adequate protein intake (1.2 g/kg/d).</p>
      </sec>
      <sec id="article-91332.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Uremic encephalopathy is a clinical syndrome without a single set of diagnostic criteria. Patients may present with nonspecific signs and symptoms such as fatigue, anorexia, nausea, and confusion. The clinical presentation is variable, and differential diagnoses to consider include hypertensive encephalopathy, hyperosmolar coma, metabolic encephalopathy, and drug toxicity.&#x000a0;</p>
        <p>While nephrologists&#x000a0;are&#x000a0;critical in caring for patients with uremic encephalopathy, it is essential to have an interprofessional team of specialists, including neurologists, radiologists, vascular radiologists, and urologists. Nurses are also crucial members of the interprofessional healthcare team, as they assist in monitoring patients clinically, initiating hemodialysis, evaluating fistulas, identifying post-procedural complications, and providing essential education to patients and their families. Pharmacists are crucial for patient care in hemodialysis treatment, ensuring safe and effective medication use, preventing medication-related issues, and adjusting dosing schedules to optimize drug effectiveness around the dialysis schedule. Radiologists are critical in identifying causes, evaluating abnormalities on MRI or CT scans, and correlating clinical and imaging findings to rule out other diagnoses. Interprofessional collaboration is essential for the early identification of uremic encephalopathy and prompt initiation of renal replacement therapy to prevent complications and reduce mortality.</p>
        <p>The interprofessional care model relies on open communication among all team members, ensuring accurate and updated records of interventions and patient interactions, which are crucial for achieving optimal patient outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-91332.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91332&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91332">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/uremic-encephalopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=91332">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/91332/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=91332">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-91332.s16">
        <title>References</title>
        <ref id="article-91332.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Hostetter</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Uremia.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Sep</month>
            <day>27</day>
            <volume>357</volume>
            <issue>13</issue>
            <fpage>1316</fpage>
            <page-range>1316-25</page-range>
            <pub-id pub-id-type="pmid">17898101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biasioli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Feriani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiaramonte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>La Greca</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Uremic encephalopathy: an updating.</article-title>
            <source>Clin Nephrol</source>
            <year>1986</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">3516476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seifter</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Uremic encephalopathy and other brain disorders associated with renal failure.</article-title>
            <source>Semin Neurol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-43</page-range>
            <pub-id pub-id-type="pmid">21590619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Husain-Syed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Uremic encephalopathy.</article-title>
            <source>Kidney Int</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>227</fpage>
            <page-range>227-241</page-range>
            <pub-id pub-id-type="pmid">34736971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Betjes</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Uremia-Associated Ageing of the Thymus and Adaptive Immune Responses.</article-title>
            <source>Toxins (Basel)</source>
            <year>2020</year>
            <month>Apr</month>
            <day>03</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">32260178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Hostler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Schlader</surname>
                <given-names>ZJ</given-names>
              </name>
            </person-group>
            <article-title>Both hyperthermia and dehydration during physical work in the heat contribute to the risk of acute kidney injury.</article-title>
            <source>J Appl Physiol (1985)</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>715</fpage>
            <page-range>715-728</page-range>
            <pub-id pub-id-type="pmid">32078468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balestracci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ezquer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elmo</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Molini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thorel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Torrents</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toledo</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>1873</fpage>
            <page-range>1873-8</page-range>
            <pub-id pub-id-type="pmid">25895445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prencipe</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Del Giudice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Giorgio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aucella</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Uremic encephalopathy in regular dialysis treatment: uremic stroke?].</article-title>
            <source>G Ital Nefrol</source>
            <year>2014</year>
            <season>Mar-Apr</season>
            <volume>31</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">24777922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nomoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scurlock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bronster</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Dexmedetomidine controls twitch-convulsive syndrome in the course of uremic encephalopathy.</article-title>
            <source>J Clin Anesth</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>646</fpage>
            <page-range>646-8</page-range>
            <pub-id pub-id-type="pmid">22137518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehman</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Idrees</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Shoukat</surname>
              </name>
            </person-group>
            <article-title>Outcome of End-Stage Renal Disease Patients with Advanced Uremia and Acidemia.</article-title>
            <source>J Coll Physicians Surg Pak</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-5</page-range>
            <pub-id pub-id-type="pmid">26787028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popkov</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Silachev</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Zalevsky</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Zorov</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Plotnikov</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>Mitochondria as a Source and a Target for Uremic Toxins.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jun</month>
            <day>25</day>
            <volume>20</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">31242575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perna</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Di Nunzio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amoresano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pane</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fontanarosa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vigorito</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cirillo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zacchia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trepiccione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ingrosso</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Divergent behavior of hydrogen sulfide pools and of the sulfur metabolite lanthionine, a novel uremic toxin, in dialysis patients.</article-title>
            <source>Biochimie</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>126</volume>
            <fpage>97</fpage>
            <page-range>97-107</page-range>
            <pub-id pub-id-type="pmid">27129884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uchiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishibashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Uremic encephalopathy in patients undergoing assisted peritoneal dialysis: a case series and literature review.</article-title>
            <source>CEN Case Rep</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-279</page-range>
            <pub-id pub-id-type="pmid">31177383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Isozaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yousuke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Terasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Otagiri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier.</article-title>
            <source>J Neurochem</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>1051</fpage>
            <page-range>1051-9</page-range>
            <pub-id pub-id-type="pmid">16445853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Deyn</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eloot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glorieux</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Guanidino compounds as uremic (neuro)toxins.</article-title>
            <source>Semin Dial</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>340</fpage>
            <page-range>340-5</page-range>
            <pub-id pub-id-type="pmid">19708978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moe</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sprague</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Uremic encephalopathy.</article-title>
            <source>Clin Nephrol</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-6</page-range>
            <pub-id pub-id-type="pmid">7834918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leong</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sirich</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies.</article-title>
            <source>Toxins (Basel)</source>
            <year>2016</year>
            <month>Nov</month>
            <day>30</day>
            <volume>8</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">27916890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaziri</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Oxidative stress in uremia: nature, mechanisms, and potential consequences.</article-title>
            <source>Semin Nephrol</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>469</fpage>
            <page-range>469-73</page-range>
            <pub-id pub-id-type="pmid">15490413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drew</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Sarnak</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>782</fpage>
            <page-range>782-790</page-range>
            <pub-id pub-id-type="pmid">31378643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flythe</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hostetter</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Assessing Clinical Relevance of Uremic Toxins.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>07</day>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-183</page-range>
            <pub-id pub-id-type="pmid">30665925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Satomura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozono</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for neurological complications in complete hemolytic uremic syndrome caused by Escherichia coli O157.</article-title>
            <source>Pediatr Int</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-9</page-range>
            <pub-id pub-id-type="pmid">19405919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamed</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-90</page-range>
            <pub-id pub-id-type="pmid">30501441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Uremic Encephalopathy: MR Imaging Findings and Clinical Correlation.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>1604</fpage>
            <page-range>1604-9</page-range>
            <pub-id pub-id-type="pmid">27127003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malek</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Brain consequences of acute kidney injury: Focusing on the hippocampus.</article-title>
            <source>Kidney Res Clin Pract</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-322</page-range>
            <pub-id pub-id-type="pmid">30619687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwafuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Posterior Reversible Encephalopathy Syndrome in a Patient with Severe Uremia without Hypertension.</article-title>
            <source>Intern Med</source>
            <year>2016</year>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-8</page-range>
            <pub-id pub-id-type="pmid">26726088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jabbari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vaziri</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>The nature, consequences, and management of neurological disorders in chronic kidney disease.</article-title>
            <source>Hemodial Int</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>150</fpage>
            <page-range>150-160</page-range>
            <pub-id pub-id-type="pmid">28799704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mistry</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Dialysis disequilibrium syndrome prevention and management.</article-title>
            <source>Int J Nephrol Renovasc Dis</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>69</fpage>
            <page-range>69-77</page-range>
            <pub-id pub-id-type="pmid">31118737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lok</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shenoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yevzlin</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Abreo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Allon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Astor</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Glickman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moist</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vachharajani</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>RP</given-names>
              </name>
              <collab>National Kidney Foundation</collab>
            </person-group>
            <article-title>KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>4 Suppl 2</issue>
            <fpage>S1</fpage>
            <page-range>S1-S164</page-range>
            <pub-id pub-id-type="pmid">32778223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Metabolic encephalopathies.</article-title>
            <source>Neurol Clin</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>837</fpage>
            <page-range>837-82</page-range>
            <pub-id pub-id-type="pmid">22032664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91332.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frontera</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Metabolic encephalopathies in the critical care unit.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>611</fpage>
            <page-range>611-39</page-range>
            <pub-id pub-id-type="pmid">22810252</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
